Entrada Therapeutics (TRDA) Assets Average (2021 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Assets Average of $356.4 million for Q1 2026, down 29.61% year-over-year from $506.4 million in Q1 2025, and down 9.79% quarter-over-quarter from $395.1 million in Q4 2025.
Entrada Therapeutics (TRDA) Assets Average (2021 - 2026) Analysis & Trends
Entrada Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $356.4 million for Q1 2026.
- In Q1 2026, Assets Average fell 29.61% year-over-year to $356.4 million; the TTM figure through Mar 2026 stood at $356.4 million (down 29.61% YoY), while the FY2025 annual figure was $451.8 million, down 9.22% from the prior year.
- Assets Average for Q1 2026 stood at $356.4 million, down from $395.1 million in the prior quarter.
- The five-year high for Assets Average was $568.3 million in Q3 2024, with the low at $263.3 million in Q4 2022.
- The 5-year median for Assets Average is $467.6 million (2025), against an average of $428.4 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average surged 81.23% in 2023, then fell 29.61% in 2026.
- Entrada Therapeutics' Assets Average stood at $263.3 million in 2022, then surged by 81.23% to $477.1 million in 2023, then advanced by 13.28% to $540.5 million in 2024, then declined by 26.89% to $395.1 million in 2025, then decreased by 9.79% to $356.4 million in 2026.
- Business Quant data shows TRDA's Assets Average at $356.4 million in Q1 2026, $395.1 million in Q4 2025, and $430.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 317.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 317.20 Mn |
| Mar 31, 2026 | 356.45 Mn |
| Dec 31, 2025 | 395.14 Mn |
| Sep 30, 2025 | 430.84 Mn |
| Jun 30, 2025 | 467.63 Mn |
| Mar 31, 2025 | 506.40 Mn |
| Dec 31, 2024 | 540.46 Mn |
| Sep 30, 2024 | 568.28 Mn |
| Jun 30, 2024 | 546.40 Mn |
| Mar 31, 2024 | 490.02 Mn |
| Dec 31, 2023 | 477.11 Mn |
| Sep 30, 2023 | 489.51 Mn |
| Jun 30, 2023 | 484.78 Mn |
| Mar 31, 2023 | 363.81 Mn |
| Dec 31, 2022 | 263.26 Mn |
| Sep 30, 2022 | 285.19 Mn |
| Jun 30, 2022 | 306.31 Mn |
| Mar 31, 2022 | 311.27 Mn |
| Dec 31, 2021 | 219.11 Mn |